Asset profile
ML-007C-MA
Small molecule
Evidence outlook · lead readout
NCT07038876 · Schizophrenia
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT07038876: This was a randomized, quadruple-masked, placebo-controlled trial with 307 participants and a clinical primary endpoint, change in PANSS total score. Because the registry does not report whether the primary endpoint was met, the available evidence supports a moderate grade rather than a stronger conclusion.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
December 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access Research2029 (1)
March 2029 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access Research2030 (1)
February 2030 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.